Please login to the form below

Not currently logged in
Email:
Password:

Hookipa Biotech appoints new global head of research and development

Dr Igor Matushansky joins the firm from Daiichi Sankyo

Dr Igor Matushansky

Hookipa Biotech has appointed Dr Igor Matushansky as its global head, research and development in a role that focuses on strategic priorities.

Previously global head of translational development for oncology at Daiichi Sankyo, Matushansky has experience in early oncology therapeutic programmes, strategy and development.

He said: “It’s an exciting time to join the Hookipa team and I am very eager to share my experience in drug development to further its mission to help patients.”

Matushansky has also previously worked for Novartis’ oncology translational medicine unit as clinical programme lead.

Joern Aldag, CEO at Hookipa Biotech, said: “Dr Matushansky’s valuable experience heading up R&D units at big pharma companies coupled with his significant immuno-oncology expertise will be transformative to Hookipa as we expand our company from prophylactic to therapeutic immuno-oncology focused therapies.

“I look forward to working together to achieve our goals and strategic priorities for 2017 and beyond.”

22nd March 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics